Australian ADHD Panel Said To Have Members With Drug Firm Ties
This article was originally published in PharmAsia News
An Australian newspaper says physicians and others serving on a panel that sets ADHD treatment guidelines have financial connections to several large drug makers. The Daily Telegraph identified seven of the 10 members of the guideline-setting committee who it said received funds or financial help from drug makers such as Eli Lilly, Celltech and Shire Pharmaceuticals, all makers of ADHD drugs the panel was considering. Among the advice in the guidelines is a warning to ignore alternative treatments, such as diet and exercise, on grounds there is little evidence they are effective. (Click here for more
You may also be interested in...
Mereo BioPharma’s completed private placement in the US will support clinical studies of its candidate immuno-oncology product etigilimab and a later-stage anti-sclerotin antibody product with potential in the treatment of brittle bone disease.
While the AAM is lobbying for a renewed focus on domestic drug production amid fresh concerns about the globalization of the US pharmaceutical drug supply chain, the association has urged US Congress to have confidence in FDA oversight, insisting that “the US has one of the safest drug supply chains in the world.”
Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.